4 - FibroBiologics, Inc. (0001958777) (Issuer)

4 - FibroBiologics, Inc. (0001958777) (Issuer)

4 - FibroBiologics, Inc. (0001958777) (Issuer)

4 - FibroBiologics, Inc. (0001958777) (Issuer)

4 - FibroBiologics, Inc. (0001958777) (Issuer)

4 - FibroBiologics, Inc. (0001958777) (Issuer)

4 - FibroBiologics, Inc. (0001958777) (Issuer)

4 - FibroBiologics, Inc. (0001958777) (Issuer)

4 - FibroBiologics, Inc. (0001958777) (Issuer)

4 - FibroBiologics, Inc. (0001958777) (Issuer)

HOUSTON, April 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics' unique fibroblast cell-based approach for the potential treatment of chronic diseases at The Cell & Gene Meeting On The Mediterranean (Med) in Rome, Italy, from April 15-17, 2025. The Cell & Gene Meeting on the Med is the leading conference bringing together the Advanced Thera

HOUSTON, April 08, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics") , a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the opening of a new laboratory facility that will expand the company's ability to pioneer additional candidates for chronic disease-focused indications leveraging its novel fibroblast-based technology. The new laboratory space will increase the company's pace of discovery for potential therapeutics including multiple chronic disease indications and will enhance the devel

HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced a significant advancement in neurodegenerative disease research. Leveraging the well-established Cuprizone animal model, FibroBiologics has demonstrated that intravenous fibroblasts can facilitate remyelination. FibroBiologics' Cuprizone animal model study demonstrated a statistically significant increase in myelin expression within seven weeks after both single and multiple

Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices after successfully passing all required safety testing Preparations for Phase 1/2 clinical trial in Australia utilizing CYWC628 to treat diabetic foot ulcers are proceeding with plans to initiate in the second quarter of 2025 Cash and cash equivalents of approximately $14.0 million at December 31, 2024 HOUSTON, March 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic dis

HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its 2025 Annual Meeting of Stockholders will take place on June 12, 2025, at 11 a.m. CDT, exclusively through a virtual format. The record date for determination of stockholders entitled to vote at the annual meeting is April 14, 2025. About FibroBiologicsBased in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of tr

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics' unique fibroblast cell-based approach for the potential treatment of chronic diseases at The German-Nordic Joint Extracellular Matrix Meeting in Freiburg, Germany, from March 26-28, 2025. The joint meeting is an annual opportunity to showcase advances in extracellu

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum, held March 13th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3DIWqav The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through March 18th. To facilitate investor relations scheduling and to view a complete calend

NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum March 13th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT:   https://bit.ly/4hnure6 It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. "We look forward to bringing together innovators from the life sciences sector," s

This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation. HOUSTON, March 04, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics") , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods employing fibroblasts to improve mitochondrial performance in cells. Mitochondria are critical organelles responsible for cellular

HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it will host an in-person analyst day at the New York Marriott Marquis on February 12, 2025, at 2:00 p.m. ET. The event will feature presentations from the following members of the Company's management: Pete O'Heeron, Chief Executive OfficerHamid Khoja, PhD, Chief Scientific OfficerRobert Hoffman, Interim Chief Financial Officer The event will highlight FibroBiol

Rodman & Renshaw initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

H.C. Wainwright initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

Maxim Group initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

DEFA14A - FibroBiologics, Inc. (0001958777) (Filer)

DEF 14A - FibroBiologics, Inc. (0001958777) (Filer)

10-K - FibroBiologics, Inc. (0001958777) (Filer)

SCHEDULE 13G - FibroBiologics, Inc. (0001958777) (Subject)

EFFECT - FibroBiologics, Inc. (0001958777) (Filer)

8-K - FibroBiologics, Inc. (0001958777) (Filer)

S-3 - FibroBiologics, Inc. (0001958777) (Filer)

8-K - FibroBiologics, Inc. (0001958777) (Filer)

EFFECT - FibroBiologics, Inc. (0001958777) (Filer)

POS AM - FibroBiologics, Inc. (0001958777) (Filer)

4 - FibroBiologics, Inc. (0001958777) (Issuer)

4 - FibroBiologics, Inc. (0001958777) (Issuer)

HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today it is set to join the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them b

HOUSTON, March 6, 2024 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the appointment of Ruben A. Garcia as General Counsel. He will report to Pete O'Heeron, FibroBiologics' Founder, Chairman and Chief Executive Officer, and be an integral member of the executive leadership team.   "The addition of Ruben as our General Counsel rep